Companies ›Healthcare ›2630.HK

2630.HK — HKEX Pharmaceuticals

Vigonvita Life Sciences Co Ltd

HK$82,00

Open in Charts → Attach watcher ⌖

— —

HKD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Vigonvita Life Sciences Co Ltd is a pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products.

Business. Vigonvita Life Sciences Co Ltd (2630.HK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is listed on the Hong Kong Stock Exchange and operates within the broader pharmaceuticals and medical research sector. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 2630.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 2630.HK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Vigonvita Life Sciences Co Ltd (2630.HK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is listed on the Hong Kong Stock Exchange and operates within the broader pharmaceuticals and medical research sector. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

Vigonvita Life Sciences has a fully diluted share count of 167,597,800 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

Profitability and return metrics are not available for comparison to industry benchmarks, as no valuation snapshot data is provided. This limits the ability to assess the company's performance relative to its peers in the Pharmaceuticals industry.

Segment and geographic exposure details are not disclosed in the available data, making it difficult to evaluate revenue concentration or geographic diversification.

Growth trajectory data is not available in the provided outlook, as no numeric deltas or revenue history is included in the input. This limits the ability to assess the company's future growth potential.

Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, as there is no difference between basic and diluted shares outstanding.

Recent events, including filings and transcripts, are not detailed in the input data, preventing an assessment of recent corporate developments or strategic shifts.

Key takeaways

Vigonvita Life Sciences is a pharmaceutical company with no current dilution risk.
Liquidity risk could not be assessed due to missing balance-sheet data.
No profitability or return metrics are available for comparison to industry benchmarks.
Growth trajectory and segment performance data are not disclosed.
Recent corporate events or strategic developments are not detailed in the available data.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

HK$82,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Vigonvita Life Sciences Co Ltd Market data — financials · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

2630.HKCanonical

HKEX · HKD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread